Search

Displaying results 1701 - 1710 of 10000 in total
  1. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    Ferumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [ … [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain.

    Synonyms: Ferumoxytol non-stoichiometric magnetiteCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [L42340] It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. … [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.

  3. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]

  4. Drug

    Ibutilide

    go.drugbank.com/drugs/DB00308
    Approved

    Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations.

    Synonyms: N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
  5. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.

    Categories: Histamine H1 Antagonists, Non-Sedating
  6. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.

  7. Drug

    Calfactant

    go.drugbank.com/drugs/DB06415
    ApprovedInvestigational

    Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. … It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline.

  8. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    As it does not contain von Willebrand factor it is not indicated in von Willebrand’s disease [L41170]. … in the 1980s [A31551, A32272, L2177].

  9. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles. … Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin.

  10. Drug

    Albiglutide

    go.drugbank.com/drugs/DB09043
    ApprovedInvestigationalWithdrawn

    Albiglutide was approved on April 15, 2014 by the FDA. … Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).

    Categories: Drugs Used in Diabetes